Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06TKI
|
|||
| Former ID |
DIB012998
|
|||
| Drug Name |
CHR-3996
|
|||
| Synonyms |
CCT-075453; CHR-2504; HDAC inhibitors, Chroma Therapeutics; Histone deacetylase inhibitors, Chroma
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Lymphoma [ICD-11: 2A80-2A86; ICD-10: C81-C86; ICD-9: 202] | Phase 1/2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [2], [3] | ||
| Company |
Chroma Therapeutics Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H19FN6O2
|
|||
| Canonical SMILES |
C1C2C(C2NCC3=NC4=C(C=C3)C=C(C=C4)F)CN1C5=NC=C(C=N5)C(=O)NO
|
|||
| InChI |
1S/C20H19FN6O2/c21-13-2-4-17-11(5-13)1-3-14(25-17)8-22-18-15-9-27(10-16(15)18)20-23-6-12(7-24-20)19(28)26-29/h1-7,15-16,18,22,29H,8-10H2,(H,26,28)/t15-,16+,18?
|
|||
| InChIKey |
QRGHOAATPOLDPF-BYICEURKSA-N
|
|||
| CAS Number |
CAS 1256448-47-1
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03397706) Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8391). | |||
| REF 3 | A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.